产品说明书

Ginkgolide A

Print
Chemical Structure| 15291-75-5 同义名 : BN-52020
CAS号 : 15291-75-5
货号 : A581449
分子式 : C20H24O9
纯度 : 98%
分子量 : 408.399
MDL号 : MFCD07437829
存储条件：

粉末 Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(257.1 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • GABA receptor

    GABA receptor, Ki:14.5 μM
描述 Ginkgolide A is a highly active platelet activating factor antagonist cage molecule which was isolated from the leaves of the Ginkgo biloba L. Ginkgolide A may be one of the potential therapeutic lead compounds, especially for the treatment of cardiovascular, hepatological, and neurological diseases and disorders[3]. Ginkgolide-A (GA), a natural PXR ligand, attenuated BT in cirrhotic mice by abrogating inflammation along the gut-liver-axis, and by protecting small intestinal tight junctions (TJ)[4]. GA could suppress the expression of pro-inflammatory mediators (cyclooxygenase-2 (COX-2) and nitric oxide (NO) and pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β) in LPS-treated mouse peritoneal macrophages, mouse macrophage RAW264.7 cells, and differentiated human monocytes (dTHP-1) in vitro[5]. GA is non-toxic at high concentrations in hepatocytes. Moreover, GA was found to inhibit cellular lipogenesis and lipid accumulation by causing mitochondrial oxidative stress. GA showed hepatoprotective efficacy by inducing cellular lipoapoptosis and by inhibiting cellular inflammation[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03772847 Intravenous Alteplase Thrombol... 展开 >>ysis Neurological Improving 收起 << Phase 4 Recruiting December 1, 2019 China, Zhejiang ... 展开 >> Min Lou Recruiting Hangzhou, Zhejiang, China, 310000 Contact: Zexin Chen    13757118366    HREC2013@126.com 收起 <<
NCT02425436 Intrauterine Growth Restrictio... 展开 >>n (IUGR) 收起 << Phase 2 Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.45mL

0.49mL

0.24mL

12.24mL

2.45mL

1.22mL

24.49mL

4.90mL

2.45mL
参考文献

[1]Zhou H, Gao J, et al. Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Renal Physiol. 2012 May 15;302(10):F1234-42.

[2]Wada K, Sasaki K, et al. Isolation of bilobalide and ginkgolide A from Ginkgo biloba L. shorten the sleeping time induced in mice by anesthetics. Biol Pharm Bull. 1993 Feb;16(2):210-2.

[3]Sarkar C, Quispe C, Jamaddar S, Hossain R, Ray P, Mondal M, Abdulwanis Mohamed Z, Sani Jaafaru M, Salehi B, Islam MT, Faizal Abdull Razis A, Martorell M, Pastene-Navarrete E, Sharifi-Rad J. Therapeutic promises of ginkgolide A: A literature-based review. Biomed Pharmacother. 2020 Dec;132:110908.

[4]Mohandas S, Vairappan B. Ginkgolide-A attenuates bacterial translocation through activating PXR and improving antimicrobial peptide Reg 3A in experimental cirrhosis. Life Sci. 2020 Sep 15;257:118111.

[5]Li Y, Wu Y, Yao X, Hao F, Yu C, Bao Y, Wu Y, Song Z, Sun Y, Zheng L, Wang G, Huang Y, Sun L, Li Y. Ginkgolide A Ameliorates LPS-Induced Inflammatory Responses In Vitro and In Vivo. Int J Mol Sci. 2017 Apr 10;18(4):794.

[6]Jeong HS, Kim KH, Lee IS, Park JY, Kim Y, Kim KS, Jang HJ. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. Biomed Pharmacother. 2017 Apr;88:625-634.